Which One Is Better for Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia: Single-Target (CD19) or Dual-Target (Tandem or Sequential CD19/CD22) CAR T-Cell Therapy?

Investigators screened 219 patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were enrolled in clinical trials of either CD19 or CD19/CD22 CAR T-cell therapy.